{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:54:58Z","timestamp":1792788898511,"version":"4.5.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40266-019-00705-5","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T05:33:32Z","timestamp":1567748012000},"page":"1015-1026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6384-6458","authenticated-orcid":false,"given":"Dario","family":"Camellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Girasole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerolamo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"issue":"22","key":"705_CR1","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315(22):2442\u201358.","journal-title":"JAMA"},{"issue":"1","key":"705_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","volume":"58","author":"RC Lawrence","year":"2008","unstructured":"Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26\u201335.","journal-title":"Arthritis Rheum."},{"issue":"8","key":"705_CR3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40266-015-0284-7","volume":"32","author":"L Steel","year":"2015","unstructured":"Steel L, Khan A, Dasgupta B. Giant cell arteritis: beyond corticosteroids. Drugs Aging. 2015;32(8):591\u20139.","journal-title":"Drugs Aging"},{"issue":"8","key":"705_CR4","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","volume":"69","author":"S Raheel","year":"2017","unstructured":"Raheel S, Shbeeb I, Crowson CS, Matteson EL. Epidemiology of polymyalgia rheumatica 2000\u20132014 and examination of incidence and survival trends over 45\u00a0years: a population-based study. Arthritis Care Res (Hoboken). 2017;69(8):1282\u20135.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"7","key":"705_CR5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/ard.49.7.521","volume":"49","author":"MA Cimmino","year":"1990","unstructured":"Cimmino MA, Caporali R, Montecucco CM, Rovida S, Baratelli E, Broggini M. A seasonal pattern in the onset of polymyalgia rheumatica. Ann Rheum Dis. 1990;49(7):521\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"1 Suppl. 109","key":"705_CR6","first-page":"S28","volume":"36","author":"S Hysa","year":"2018","unstructured":"Hysa S, Sobrero A, Camellino D, Pizzorni C, Cutolo M, Cimmino MA. A seasonal onset for polymyalgia rheumatica? Clin Exp Rheumatol. 2018;36(1 Suppl. 109):S28.","journal-title":"Clin Exp Rheumatol"},{"key":"705_CR7","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2147\/CLEP.S158293","volume":"10","author":"C Brault","year":"2018","unstructured":"Brault C, Riis AH, Mor A, Duhaut P, Thomsen RW. Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study. Clin Epidemiol. 2018;10:1533\u201343.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"705_CR8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4081\/reumatismo.2017.1033","volume":"69","author":"MA Cimmino","year":"2017","unstructured":"Cimmino MA, Camellino D. Large vessel vasculitis: is it more common than usually assumed? Reumatismo. 2017;69(4):143\u20136.","journal-title":"Reumatismo."},{"issue":"4","key":"705_CR9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0049-0172(84)90012-X","volume":"13","author":"LA Healey","year":"1984","unstructured":"Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum. 1984;13(4):322\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"705_CR10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/rheumatology\/39.3.283","volume":"39","author":"JT Gran","year":"2000","unstructured":"Gran JT, Myklebust G. The incidence and clinical characteristics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis: a prospective study of 231 cases. Rheumatology (Oxford). 2000;39(3):283\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"705_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4081\/reumatismo.2018.1048","volume":"70","author":"G Guggino","year":"2018","unstructured":"Guggino G, Ferrante A, Macaluso F, Triolo G, Ciccia F. Pathogenesis of polymyalgia rheumatica. Reumatismo. 2018;70(1):10\u20137.","journal-title":"Reumatismo."},{"issue":"3","key":"705_CR12","first-page":"517","volume":"26","author":"C Salvarani","year":"1999","unstructured":"Salvarani C, Cantini F, Olivieri I, Hunder GS. Polymyalgia rheumatica: a disorder of extraarticular synovial structures? J Rheumatol. 1999;26(3):517\u201321.","journal-title":"J Rheumatol"},{"key":"705_CR13","first-page":"1837","volume":"28","author":"D McGonagle","year":"2001","unstructured":"McGonagle D, Pease C, Marzo-Ortega H, et al. Comparison of extracapsular changes by magnetic resonance imaging in patients with rheumatoid arthritis and polymyalgia rheumatica. J Rheumatol. 2001;28:1837\u201341.","journal-title":"J Rheumatol"},{"issue":"9","key":"705_CR14","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/art.24770","volume":"60","author":"D Camellino","year":"2009","unstructured":"Camellino D, Sambuceti G, Morbelli S, Cimmino MA, Camellino D, Sambuceti G, et al. The multifaceted pathogenesis of polymyalgia rheumatica\/giant cell arteritis. Arthritis Rheum. 2009;60(9):2771.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"705_CR15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/rheumatology\/keq450","volume":"51","author":"D Camellino","year":"2012","unstructured":"Camellino D, Cimmino MA. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford). 2012;51(1):77\u201386.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"705_CR16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12026-016-8817-7","volume":"65","author":"M-T Arango","year":"2017","unstructured":"Arango M-T, Perricone C, Kivity S, Cipriano E, Ceccarelli F, Valesini G, et al. HLA-DRB1 the notorious gene in the mosaic of autoimmunity. Immunol Res. 2017;65(1):82\u201398.","journal-title":"Immunol Res"},{"issue":"4","key":"705_CR17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1399-0039.2010.01466.x","volume":"75","author":"SGE Marsh","year":"2010","unstructured":"Marsh SGE, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291\u2013455.","journal-title":"Tissue Antigens"},{"issue":"10","key":"705_CR18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.humimm.2018.07.229","volume":"79","author":"SGE Marsh","year":"2018","unstructured":"Marsh SGE. Nomenclature for factors of the HLA system, update May 2018. Hum Immunol. 2018;79(10):752\u20136.","journal-title":"Hum Immunol"},{"issue":"6","key":"705_CR19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41584-019-0219-5","volume":"15","author":"R Busch","year":"2019","unstructured":"Busch R, Kollnberger S, Mellins ED. HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications. Nat Rev Rheumatol. 2019;15(6):364\u201381.","journal-title":"Nat Rev Rheumatol"},{"issue":"16","key":"705_CR20","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.2015.3435","volume":"313","author":"S Viatte","year":"2015","unstructured":"Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W, et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA. 2015;313(16):1645\u201356.","journal-title":"JAMA"},{"issue":"10","key":"705_CR21","first-page":"2148","volume":"29","author":"S Jacobsen","year":"2002","unstructured":"Jacobsen S, Baslund B, Madsen HO, Tvede N, Svejgaard A, Garred P. Mannose-binding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis. J Rheumatol. 2002;29(10):2148\u201353.","journal-title":"J Rheumatol"},{"issue":"11","key":"705_CR22","first-page":"2140","volume":"25","author":"A Dababneh","year":"1998","unstructured":"Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol. 1998;25(11):2140\u20135.","journal-title":"J Rheumatol"},{"issue":"6","key":"705_CR23","first-page":"1326","volume":"26","author":"MA Gonz\u00e1lez-Gay","year":"1999","unstructured":"Gonz\u00e1lez-Gay MA, Garc\u00eda-Porr\u00faa C, V\u00e1zquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10\u00a0year study. J Rheumatol. 1999;26(6):1326\u201332.","journal-title":"J Rheumatol"},{"issue":"1","key":"705_CR24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.semarthrit.2003.12.001","volume":"34","author":"VM Mart\u00ednez-Taboda","year":"2004","unstructured":"Mart\u00ednez-Taboda VM, Bartolome MJ, Lopez-Hoyos M, Blanco R, Mata C, Calvo J, et al. HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: influence on clinical subgroups and prognosis. Semin Arthritis Rheum. 2004;34(1):454\u201364.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"705_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/ard.58.5.303","volume":"58","author":"C Salvarani","year":"1999","unstructured":"Salvarani C, Boiardi L, Mantovani V, Ranzi A, Cantini F, Olivieri I, et al. HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann Rheum Dis. 1999;58(5):303\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"705_CR26","first-page":"112","volume":"23","author":"P Elling","year":"1996","unstructured":"Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol. 1996;23(1):112\u20139.","journal-title":"J Rheumatol"},{"issue":"5","key":"705_CR27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/ard.2004.025320","volume":"64","author":"R Alvarez-Lafuente","year":"2005","unstructured":"Alvarez-Lafuente R, Fern\u00e1ndez-Guti\u00e9rrez B, Jover JA, J\u00fadez E, Loza E, Clemente D, et al. Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis. 2005;64(5):780\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"705_CR28","first-page":"361","volume":"26","author":"P Duhaut","year":"1999","unstructured":"Duhaut P, Bosshard S, Calvet A, Pinede L, Demolombe-Rague S, Dumontet C, et al. Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de Recherche sur l\u2019Art\u00e9rite \u00e0 Cellules G\u00e9antes. J Rheumatol. 1999;26(2):361\u20139.","journal-title":"J Rheumatol."},{"issue":"11","key":"705_CR29","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","volume":"64","author":"M Samson","year":"2012","unstructured":"Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64(11):3788\u201398.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"705_CR30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00296-009-0949-9","volume":"30","author":"C Dejaco","year":"2010","unstructured":"Dejaco C, Duftner C, Klauser A, Schirmer M. Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatica. Rheumatol Int. 2010;30(3):297\u2013303.","journal-title":"Rheumatol Int"},{"issue":"11","key":"705_CR31","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1136\/annrheumdis-2012-201660","volume":"72","author":"C Dejaco","year":"2013","unstructured":"Dejaco C, Duftner C, Al-Massad J, Wagner AD, Park J-K, Fessler J, et al. NKG 2 D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2013;72(11):1852\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"705_CR32","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/art.38625","volume":"66","author":"KSM van der Geest","year":"2014","unstructured":"van der Geest KSM, Abdulahad WH, Chalan P, Rutgers A, Horst G, Huitema MG, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2014;66(7):1927\u201338.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"705_CR33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98\u2013106.","journal-title":"Am J Clin Oncol"},{"key":"705_CR34","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.3389\/fimmu.2018.02306","volume":"9","author":"C Paluch","year":"2018","unstructured":"Paluch C, Santos AM, Anzilotti C, Cornall RJ, Davis SJ. Immune checkpoints as therapeutic targets in autoimmunity. Front Immunol. 2018;9:2306.","journal-title":"Front Immunol."},{"issue":"10","key":"705_CR35","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377\u201385.","journal-title":"Ann Oncol"},{"issue":"3","key":"705_CR36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","volume":"77","author":"M Kostine","year":"2018","unstructured":"Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"705_CR37","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","volume":"66","author":"BL Goldstein","year":"2014","unstructured":"Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol. 2014;66(3):768\u20139.","journal-title":"Arthritis Rheumatol."},{"key":"705_CR38","doi-asserted-by":"publisher","unstructured":"Betrains A, Blockmans DE. Immune checkpoint inhibitor-associated polymyalgia rheumatica\/giant cell arteritis occurring in a patient after treatment with nivolumab. J Clin Rheumatol. 2019. \n                    https:\/\/doi.org\/10.1097\/rhu.0000000000001012\n                    \n                  \n                           (epub ahead of print).","DOI":"10.1097\/rhu.0000000000001012"},{"key":"705_CR39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejca.2018.07.318","volume":"103","author":"B Robilliard","year":"2018","unstructured":"Robilliard B, Arnaud E, Gastaud L, Broner J. A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica. Eur J Cancer. 2018;103:281\u20133.","journal-title":"Eur J Cancer"},{"issue":"5","key":"705_CR40","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/eji.201242529","volume":"43","author":"FJ Ward","year":"2013","unstructured":"Ward FJ, Dahal LN, Wijesekera SK, Abdul-Jawad SK, Kaewarpai T, Xu H, et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol. 2013;43(5):1274\u201385.","journal-title":"Eur J Immunol"},{"issue":"2","key":"705_CR41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13317-010-0011-7","volume":"1","author":"D Saverino","year":"2010","unstructured":"Saverino D, Simone R, Bagnasco M, Pesce G. The soluble CTLA-4 receptor and its role in autoimmune diseases: an update. Autoimmun Highlights. 2010;1(2):73\u201381.","journal-title":"Autoimmun Highlights."},{"issue":"9","key":"705_CR42","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/intimm\/dxp069","volume":"21","author":"R Simone","year":"2009","unstructured":"Simone R, Brizzolara R, Chiappori A, Milintenda-Floriani F, Natale C, Greco L, et al. A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury. Int Immunol. 2009;21(9):1037\u201345.","journal-title":"Int Immunol"},{"issue":"1","key":"705_CR43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13075-016-1075-1","volume":"18","author":"LN Dahal","year":"2016","unstructured":"Dahal LN, Basu N, Youssef H, Khanolkar RC, Barker RN, Erwig LP, et al. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther. 2016;18(1):180.","journal-title":"Arthritis Res Ther."},{"issue":"Suppl.","key":"705_CR44","first-page":"A432","volume":"77","author":"D Camellino","year":"2018","unstructured":"Camellino D, Marchiano M, Pesce G, Bianchi G, Bagnasco M, Cimmino MA, et al. THU0440 soluble CTLA-4 is elevated in patients with polymyalgia rheumatica and correlates with vascular inflammation detected by PET\/CT. Ann Rheum Dis. 2018;77(Suppl.):A432.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"705_CR45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161\u201370.","journal-title":"N Engl J Med"},{"issue":"2","key":"705_CR46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s40674-016-0043-x","volume":"2","author":"R Watanabe","year":"2016","unstructured":"Watanabe R, Goronzy JJ, Berry G, Liao YJ, Weyand CM. Giant cell arteritis: from pathogenesis to therapeutic management. Curr Treat Options Rheumatol. 2016;2(2):126\u201337.","journal-title":"Curr Treat Options Rheumatol."},{"issue":"18","key":"705_CR47","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","volume":"137","author":"H Zhang","year":"2018","unstructured":"Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137(18):1934\u201348.","journal-title":"Circulation"},{"issue":"1","key":"705_CR48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.2008.103663","volume":"69","author":"L Alvarez-Rodr\u00edguez","year":"2010","unstructured":"Alvarez-Rodr\u00edguez L, Lopez-Hoyos M, Mata C, Marin MJ, Calvo-Alen J, Blanco R, et al. Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis. 2010;69(1):263\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"705_CR49","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/acr.20043","volume":"62","author":"A Garc\u00eda-Mart\u00ednez","year":"2010","unstructured":"Garc\u00eda-Mart\u00ednez A, Hern\u00e1ndez-Rodr\u00edguez J, Esp\u00edgol-Frigol\u00e9 G, Prieto-Gonz\u00e1lez S, Butjosa M, Segarra M, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor \u03b1 and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res (Hoboken). 2010;62(6):835\u201341.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"2","key":"705_CR50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"705_CR51","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/ard.60.11.1021","volume":"60","author":"R Caporali","year":"2001","unstructured":"Caporali R, Montecucco C, Epis O, Bobbio-Pallavicini F, Maio T, Cimmino MA. Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. Ann Rheum Dis. 2001;60(11):1021\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"705_CR52","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","volume":"71","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71(4):484\u201392.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"705_CR53","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/rheumatology\/key431","volume":"58","author":"Ciro Manzo","year":"2019","unstructured":"Manzo C, Milchert M, Natale M, Brzosko M. Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis. Rheumatology (Oxford). 2019. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/key431\n                    \n                  \n                           (epub ahead of print).","journal-title":"Rheumatology"},{"issue":"1","key":"705_CR54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sarh.2000.8366","volume":"30","author":"F Cantini","year":"2000","unstructured":"Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum. 2000;30(1):17\u201324.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"705_CR55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/art.1780390220","volume":"39","author":"SM Helfgott","year":"1996","unstructured":"Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum. 1996;39(2):304\u20137.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"705_CR56","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/annrheumdis-2011-200413","volume":"71","author":"NT Baerlecken","year":"2012","unstructured":"Baerlecken NT, Linnemann A, Gross WL, Moosig F, Vazquez-Rodriguez TR, Gonzalez-Gay MA, et al. Association of ferritin autoantibodies with giant cell arteritis\/polymyalgia rheumatica. Ann Rheum Dis. 2012;71(6):943\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"705_CR57","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/annrheumdis-2013-204167","volume":"73","author":"P Macchioni","year":"2014","unstructured":"Macchioni P, Boiardi L, Catanoso M, Pazzola G, Salvarani C. Performance of the new 2012 EULAR\/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis. 2014;73(6):1190\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"705_CR58","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3899\/jrheum.151103","volume":"43","author":"G Ozen","year":"2016","unstructured":"Ozen G, Inanc N, Unal AU, Bas S, Kimyon G, Kisacik B, et al. Assessment of the new 2012 EULAR\/ACR clinical classification criteria for polymyalgia rheumatica: a prospective multicenter study. J Rheumatol. 2016;43(5):893\u2013900.","journal-title":"J Rheumatol"},{"issue":"5","key":"705_CR59","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3899\/jrheum.160232","volume":"43","author":"D Camellino","year":"2016","unstructured":"Camellino D, Cimmino MA. Are the new ACR\/EULAR criteria the ultimate answer for polymyalgia rheumatica classification? J Rheumatol. 2016;43(5):836\u20138.","journal-title":"J Rheumatol"},{"issue":"5","key":"705_CR60","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/ard.38.5.434","volume":"38","author":"HA Bird","year":"1979","unstructured":"Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979;38(5):434\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"705_CR61","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2169\/internalmedicine1962.28.452","volume":"28","author":"M Nobunaga","year":"1989","unstructured":"Nobunaga M, Yoshioka K, Yasuda M, Shingu M, Nobunaga M, Yoshioka K, et al. Clinical studies of polymyalgia rheumatica: a proposal of diagnostic criteria. Jpn J Med. 1989;28(4):452\u20136.","journal-title":"Jpn J Med."},{"issue":"4","key":"705_CR62","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3899\/jrheum.110977","volume":"39","author":"EL Matteson","year":"2012","unstructured":"Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA, Schirmer M, Salvarani C, et al. Patient-reported outcomes in polymyalgia rheumatica. J Rheumatol. 2012;39(4):795\u2013803.","journal-title":"J Rheumatol"},{"issue":"8","key":"705_CR63","first-page":"1335","volume":"20","author":"HJ Haga","year":"1993","unstructured":"Haga HJ, Eide GE, Brun J, Johansen A, Langmark F. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20(8):1335\u20139.","journal-title":"J Rheumatol"},{"issue":"2","key":"705_CR64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/03009740252937649","volume":"31","author":"L Niccoli","year":"2002","unstructured":"Niccoli L, Salvarani C, Baroncelli G, Padula A, Olivieri I, Cantini F. Renal cell carcinoma mimicking polymyalgia rheumatica: clues for a correct diagnosis. Scand J Rheumatol. 2002;31(2):103\u20136.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"705_CR65","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrrheum.2014.138","volume":"10","author":"B Manger","year":"2014","unstructured":"Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10(11):662\u201370.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"705_CR66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4081\/reumatismo.2018.1031","volume":"70","author":"S Muller","year":"2018","unstructured":"Muller S, Hider S, Helliwell T, Partington R, Mallen C. The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome. Reumatismo. 2018;70(1):23\u201334.","journal-title":"Reumatismo."},{"issue":"7","key":"705_CR67","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/annonc\/mdu144","volume":"25","author":"M Fallah","year":"2014","unstructured":"Fallah M, Liu X, Ji J, F\u00f6rsti A, Sundquist K, Hemminki K. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. Ann Oncol. 2014;25(7):1397\u2013404.","journal-title":"Ann Oncol"},{"issue":"10","key":"705_CR68","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/annonc\/mdu365","volume":"25","author":"M Fallah","year":"2014","unstructured":"Fallah M, Liu X, Ji J, F\u00f6rsti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol. 2014;25(10):2025\u201330.","journal-title":"Ann Oncol"},{"issue":"12","key":"705_CR69","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.jse.2014.08.001","volume":"23","author":"T Teunis","year":"2014","unstructured":"Teunis T, Lubberts B, Reilly BT, Ring D. A systematic review and pooled analysis of the prevalence of rotator cuff disease with increasing age. J Shoulder Elbow Surg. 2014;23(12):1913\u201321.","journal-title":"J Shoulder Elbow Surg"},{"issue":"12","key":"705_CR70","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/kep286","volume":"48","author":"P Macchioni","year":"2009","unstructured":"Macchioni P, Catanoso MG, Pipitone N, Boiardi L, Salvarani C. Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology. 2009;48(12):1566\u20139.","journal-title":"Rheumatology"},{"issue":"1","key":"705_CR71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-017-1499-2","volume":"20","author":"A Huwart","year":"2018","unstructured":"Huwart A, Garrigues F, Jousse-Joulin S, Marhadour T, Guellec D, Cornec D, et al. Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. Arthritis Res Ther. 2018;20(1):11.","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"705_CR72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3899\/jrheum.160090","volume":"44","author":"MC Miceli","year":"2017","unstructured":"Miceli MC, Zoli A, Peluso G, Bosello S, Gremese E, Ferraccioli G. Baseline shoulder ultrasonography is not a predictive marker of response to glucocorticoids in patients with polymyalgia rheumatica: a 12-month followup study. J Rheumatol. 2017;44(2):241\u20137.","journal-title":"J Rheumatol"},{"issue":"Suppl. 114","key":"705_CR73","first-page":"86","volume":"36","author":"M Fruth","year":"2018","unstructured":"Fruth M, Buehring B, Baraliakos X, Braun J. Use of contrast-enhanced magnetic resonance imaging of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumatica. Clin Exp Rheumatol. 2018;36(Suppl. 114):86\u201395.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"705_CR74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/rheumatology\/kex411","volume":"57","author":"CE Owen","year":"2018","unstructured":"Owen CE, Poon AMT, Lee ST, Yap LP, Zwar RB, McMenamin CM, et al. Fusion of positron emission tomography\/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica. Rheumatology (Oxford). 2018;57(2):345\u201353.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"705_CR75","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1136\/annrheumdis-2015-207395","volume":"74","author":"SL Mackie","year":"2015","unstructured":"Mackie SL, Pease CT, Fukuba E, Harris E, Emery P, Hodgson R, et al. Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids. Ann Rheum Dis. 2015;74(12):2188\u201392.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"705_CR76","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41584-019-0236-4","volume":"5","author":"D Camellino","year":"2019","unstructured":"Camellino D, Dejaco C. Should 18F-FDG-PET imaging be used in the diagnosis of GCA? Nat Rev Rheumatol. 2019;5(7):388\u201390.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"705_CR77","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s13075-014-0492-2","volume":"16","author":"D Camellino","year":"2014","unstructured":"Camellino D, Paparo F, Morbelli S, Cutolo M, Sambuceti G, Cimmino MA. Interspinous bursitis is common in polymyalgia rheumatica, but is not associated with spinal pain. Arthritis Res Ther. 2014;16(6):492.","journal-title":"Arthritis Res Ther."},{"issue":"4","key":"705_CR78","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3109\/14397595.2014.978936","volume":"25","author":"H Takahashi","year":"2015","unstructured":"Takahashi H, Yamashita H, Kubota K, Miyata Y, Okasaki M, Morooka M, et al. Differences in fluorodeoxyglucose positron emission tomography\/computed tomography findings between elderly onset rheumatoid arthritis and polymyalgia rheumatica. Mod Rheumatol. 2015;25(4):546\u201351.","journal-title":"Mod Rheumatol"},{"issue":"8","key":"705_CR79","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/rheumatology\/kew202","volume":"55","author":"M Sondag","year":"2016","unstructured":"Sondag M, Guillot X, Verhoeven F, Blagosklonov O, Prati C, Boulahdour H, et al. Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study. Rheumatology (Oxford). 2016;55(8):1452\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"705_CR80","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/rheumatology\/ket229","volume":"52","author":"MA Cimmino","year":"2013","unstructured":"Cimmino MA, Camellino D, Paparo F, Morbelli S, Massollo M, Cutolo M, et al. High frequency of capsular knee involvement in polymyalgia rheumatica\/giant cell arteritis patients studied by positron emission tomography. Rheumatology (Oxford). 2013;52(10):1865\u201372.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"705_CR81","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","volume":"46","author":"D Blockmans","year":"2007","unstructured":"Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford). 2007;46(4):672\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"705_CR82","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/ken098","volume":"47","author":"MA Cimmino","year":"2008","unstructured":"Cimmino MA, Zampogna G, Parodi M. Is FDG-PET useful in the evaluation of steroid-resistant PMR patients? Rheumatology (Oxford). 2008;47(6):926\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"705_CR83","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.semarthrit.2018.05.007","volume":"48","author":"D Prieto-Pe\u00f1a","year":"2019","unstructured":"Prieto-Pe\u00f1a D, Mart\u00ednez-Rodr\u00edguez I, Loricera J, Banzo I, Calder\u00f3n-Goercke M, Calvo-R\u00edo V, et al. Predictors of positive 18 F-FDG PET\/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. Semin Arthritis Rheum. 2019;48(4):720\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"705_CR84","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s00259-018-3973-8","volume":"45","author":"RHJA Slart","year":"2018","unstructured":"Slart RHJA, Writing group, Reviewer group, Members of EANM Cardiovascular, Members of EANM Infection & Inflammation, Members of Committees SC, et al. FDG-PET\/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018;45(7):1250\u201369.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"705_CR85","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","volume":"77","author":"C Dejaco","year":"2018","unstructured":"Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77(5):636\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"705_CR86","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799\u2013807.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"705_CR87","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/acr.23320","volume":"70","author":"I Shbeeb","year":"2018","unstructured":"Shbeeb I, Challah D, Raheel S, Crowson CS, Matteson EL. Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population. Arthritis Care Res (Hoboken). 2018;70(4):643\u20137.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"2","key":"705_CR88","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","volume":"37","author":"B Dasgupta","year":"1998","unstructured":"Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially double-blind controlled 96\u00a0week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Rheumatology. 1998;37(2):189\u201395.","journal-title":"Rheumatology"},{"issue":"1","key":"705_CR89","doi-asserted-by":"crossref","first-page":"e000426","DOI":"10.1136\/rmdopen-2016-000426","volume":"3","author":"M Cutolo","year":"2017","unstructured":"Cutolo M, Hopp M, Liebscher S, Dasgupta B, Buttgereit F. Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. RMD Open. 2017;3(1):e000426.","journal-title":"RMD Open."},{"key":"705_CR90","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1196\/annals.1351.030","volume":"1069","author":"MA Cimmino","year":"2006","unstructured":"Cimmino MA, Parodi M, Caporali R, Montecucco C. Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci. 2006;1069:315\u201321.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"705_CR91","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00296-012-2580-4","volume":"33","author":"JH Lee","year":"2013","unstructured":"Lee JH, Choi ST, Kim JS, Yoon BY, Kwok S-K, Kim HS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int. 2013;33(6):1475\u201380.","journal-title":"Rheumatol Int."},{"issue":"7","key":"705_CR92","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1529-0131(199807)41:7<1221::AID-ART12>3.0.CO;2-W","volume":"41","author":"C Salvarani","year":"1998","unstructured":"Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 1998;41(7):1221\u20136.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"705_CR93","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/art.23924","volume":"59","author":"L Pulsatelli","year":"2008","unstructured":"Pulsatelli L, Boiardi L, Pignotti E, Dolzani P, Silvestri T, Macchioni P, et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse\/recurrence risk. Arthritis Rheum. 2008;59(8):1147\u201354.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"705_CR94","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10067-018-3988-3","volume":"37","author":"A Charpentier","year":"2018","unstructured":"Charpentier A, Verhoeven F, Sondag M, Guillot X, Prati C, Wendling D. Therapeutic response to prednisone in relation to age in polymyalgia rheumatica: a comparison study. Clin Rheumatol. 2018;37(3):819\u201323.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"705_CR95","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism\/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis. 2015;74(10):1808\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"705_CR96","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004;141(7):493\u2013500.","journal-title":"Ann Intern Med"},{"issue":"3","key":"705_CR97","first-page":"395","volume":"26","author":"MA Cimmino","year":"2008","unstructured":"Cimmino MA, Salvarani C, Macchioni P, Gerli R, Bartoloni Bocci E, Montecucco C, et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol. 2008;26(3):395\u2013400.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"705_CR98","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","volume":"146","author":"C Salvarani","year":"2007","unstructured":"Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. Ann Intern Med. 2007;146(9):631\u20139.","journal-title":"Ann Intern Med"},{"issue":"5","key":"705_CR99","doi-asserted-by":"crossref","first-page":"R176","DOI":"10.1186\/ar3140","volume":"12","author":"F Kreiner","year":"2010","unstructured":"Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther. 2010;12(5):R176.","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"705_CR100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4081\/reumatismo.2018.1062","volume":"70","author":"D Camellino","year":"2018","unstructured":"Camellino D, Dejaco C. Update on treatment of polymyalgia rheumatica. Reumatismo. 2018;70(1):59\u201366.","journal-title":"Reumatismo."},{"issue":"4","key":"705_CR101","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317\u201328.","journal-title":"N Engl J Med"},{"issue":"8","key":"705_CR102","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec V, Berthelot JM, Cornec D, Renaudineau Y, Marhadour T, Jousse-Joulin S, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75(8):1506\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"705_CR103","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","volume":"63","author":"BF Leeb","year":"2004","unstructured":"Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004;63(10):1279\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"705_CR104","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally L, Forbess L, Hatzis C, Spiera R. Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol. 2016;68(10):2550\u20134.","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"705_CR105","first-page":"S391","volume":"66","author":"EL Matteson","year":"2014","unstructured":"Matteson EL, Dasgupta B, Schmidt WA, Salvarani C, Gendi N, Galeazzi M, et al. A 2\u00a0week single-blind, randomized, 3-arm proof of concept study of the effects of secukinumab (anti-IL17 mAb), canakinumab (anti-IL-1 b mAb), or corticosteroids on initial disease activity scores in patients with PMR, followed by an open-label extension. Arthritis Rheumatol. 2014;66(10):S391.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"705_CR106","first-page":"65","volume":"32","author":"HM Kremers","year":"2005","unstructured":"Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005;32(1):65\u201373.","journal-title":"J Rheumatol"},{"issue":"3","key":"705_CR107","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/ard.2010.133850","volume":"70","author":"C Dejaco","year":"2010","unstructured":"Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS, et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis. 2010;70(3):447\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"705_CR108","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521\u201337.","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"705_CR109","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/art.1780401022","volume":"39","author":"SE Gabriel","year":"1997","unstructured":"Gabriel SE, Sunku J, Salvarani C, O\u2019Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;39(10):1873\u20138.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"705_CR110","doi-asserted-by":"crossref","first-page":"e000521","DOI":"10.1136\/rmdopen-2017-000521","volume":"4","author":"LYH Lai","year":"2018","unstructured":"Lai LYH, Harris E, West RM, Mackie SL. Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis. RMD Open. 2018;4(1):e000521.","journal-title":"RMD Open."},{"issue":"1","key":"705_CR111","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13075-018-1757-y","volume":"20","author":"R Partington","year":"2018","unstructured":"Partington R, Helliwell T, Muller S, Abdul Sultan A, Mallen C. Comorbidities in polymyalgia rheumatica: a systematic review. Arthritis Res Ther. 2018;20(1):258.","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"705_CR112","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4081\/reumatismo.2018.1039","volume":"70","author":"C Chatzigeorgiou","year":"2018","unstructured":"Chatzigeorgiou C, Mackie SL. Comorbidity in polymyalgia rheumatica. Reumatismo. 2018;70(1):35\u201343.","journal-title":"Reumatismo."},{"issue":"1","key":"705_CR113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12916-017-0987-1","volume":"16","author":"Z Paskins","year":"2018","unstructured":"Paskins Z, Whittle R, Sultan AA, Muller S, Blagojevic-Bucknall M, Helliwell T, et al. Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study. BMC Med. 2018;16(1):4.","journal-title":"BMC Med."},{"issue":"1","key":"705_CR114","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4081\/reumatismo.2017.922","volume":"69","author":"M Rossini","year":"2017","unstructured":"Rossini M, Viapiana O, Vitiello M, Malavolta N, La Montagna G, Maddali Bongi S, et al. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo. 2017;69(1):30\u20139.","journal-title":"Reumatismo."},{"issue":"Suppl. 103(1)","key":"705_CR115","first-page":"224","volume":"35","author":"C De Lorenzi","year":"2017","unstructured":"De Lorenzi C, Rosa GM, Camellino D, Morbelli S, Dorighi U, Masoero G, et al. Cardiac and aortic involvement in patients with polymyalgia rheumatica: a study with echocardiography and FDG-PET\/CT. Clin Exp Rheumatol. 2017;35(Suppl. 103(1)):224.","journal-title":"Clin Exp Rheumatol."},{"key":"705_CR116","unstructured":"Marin Zucaro NM, Scolnik M, Mollerach FB, Scaglioni V, Lo Giudice LF, Martinez PJM, Jaramillo Gallego JF, Soriano ER. Development of thoracic aortic aneurysms in patients with polymyalgia rheumatica: underdiagnosed giant cell arteritis?. Arthritis Rheumatol. 2018;70(suppl 10). \n                    https:\/\/acrabstracts.org\/abstract\/development-of-thoracic-aortic-aneurysms-in-patients-with-polymyalgia-rheumatica-underdiagnosed-giant-cell-arteritis\/\n                    \n                  . Accessed 24 Aug 2019."},{"issue":"1","key":"705_CR117","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2012-202145","volume":"73","author":"SL Mackie","year":"2014","unstructured":"Mackie SL, Hensor EMA, Morgan AW, Pease CT. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis. 2014;73(1):143\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"705_CR118","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.semarthrit.2018.05.002","volume":"48","author":"TA Kermani","year":"2019","unstructured":"Kermani TA, Diab S, Sreih AG, Cuthbertson D, Borchin R, Carette S, et al. Arterial lesions in giant cell arteritis: a longitudinal study. Semin Arthritis Rheum. 2019;48(4):707\u201313.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"705_CR119","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.pec.2014.12.013","volume":"98","author":"H Twohig","year":"2015","unstructured":"Twohig H, Mitchell C, Mallen C, Adebajo A, Mathers N. \u201cI suddenly felt I\u2019d aged\u201d: a qualitative study of patient experiences of polymyalgia rheumatica (PMR). Patient Educ Couns. 2015;98(5):645\u201350.","journal-title":"Patient Educ Couns"},{"key":"705_CR120","doi-asserted-by":"crossref","unstructured":"Camellino D, Dejaco C, Buttgereit F, Matteson EL. Treat to target: a valid concept for management of polymyalgia rheumatica and giant cell arteritis? Rheum Dis Clin N Am. 2019;45(4) (in press).","DOI":"10.1001\/jama.2020.10155"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00705-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-019-00705-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00705-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T23:42:56Z","timestamp":1599262976000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-019-00705-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":120,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1007\/s40266-019-00705-5","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"6 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding or writing assistance were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dario Camellino has received consultancy and speaker fees from AbbVie, Celgene, Janssen-Cilag, Lilly, Mylan and Sanofi; none related to this article. Andrea Giusti has received consultancy and speaker fees from Abiogen, Amgen, EffRx, Eli Lilly, Internis, Labatec, NewBridge, PharmaLink and UCB; none related to this article. Giuseppe Girasole has received speaker fees from Abiogen; none related to this article. Gerolamo Bianchi has received honoraria and\/or consulting fees from Abbvie, Abiogen, Alfa-Sigma, Amgen, BMS, Celgene, Chiesi, Eli Lilly, GSK, Janssen, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi Genzyme and Servier. Christian Dejaco has received consultancy fees and honoraria from AbbVie, Celgene, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz and UCB and unrestricted grant support from Celgene.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}